Endonovo Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Stock-Based Compensation Growth & History (ENDV)
Endonovo Therapeutics's stock-based compensation was $0 for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | −$686,747 | — |
| 2023 | 2023-12-31 | $686,747 | $641,747 | +1426.10% |
| 2022 | 2022-12-31 | $45,000 | $45,000 | — |
| 2021 | 2021-12-31 | $0 | −$57,400 | — |
| 2020 | 2020-12-31 | $57,400 | $26,388 | +85.09% |
| 2019 | 2019-12-31 | $31,012 | — | — |
Endonovo Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $0 | $0 | — |
| Q2 2023 | 2023-06-30 | $3,440 | — | — |
| Q1 2023 | 2023-03-31 | $2,560 | — | — |
| Q3 2022 | 2022-09-30 | $0 | −$20,039 | — |
| Q3 2021 | 2021-09-30 | $20,039 | −$324,529 | −94.18% |
| Q2 2021 | 2021-06-30 | $20,490 | −$25,483 | −55.43% |
| Q1 2021 | 2021-03-31 | $20,471 | $10,904 | +113.98% |
| Q3 2020 | 2020-09-30 | $344,568 | — | — |
| Q2 2020 | 2020-06-30 | $45,973 | — | — |
| Q1 2020 | 2020-03-31 | $9,567 | — | — |
Endonovo Therapeutics stock-based compensation trends
Over the last five fiscal years, Endonovo Therapeutics's stock-based compensation decreased from $31,012 to $0, a change of −$31,012. The latest reported quarter, Q2 2025, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗